<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793725</url>
  </required_header>
  <id_info>
    <org_study_id>HZ-T-PD1-APA</org_study_id>
    <nct_id>NCT03793725</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC</brief_title>
  <acronym>HZ-T-PD1-APA</acronym>
  <official_title>A Phase II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanqiao Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1
      Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular
      Carcinoma.

      This study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as
      a preoperative treatment of unresectable HCC.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 (resection rate)</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>R0 resection rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>from the first drug administration up to one year</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS</measure>
    <time_frame>from the first drug administration up to one year</time_frame>
    <description>relapse free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>SHR-1210 + Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1210</intervention_name>
    <description>Anti-PD-1 Antibody</description>
    <arm_group_label>SHR-1210 + Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Anti-angiogenic drugs</description>
    <arm_group_label>SHR-1210 + Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects voluntarily participate in this study and sign informed consent .

          -  Men or women aged 18-75 years

          -  patients with Unresectable HCC confirmed histologically or cytologically or
             clinically，At least one measurable lesion that meets the RECIST v1.1 criteria without
             local treatment.

          -  The patients can swallow pills normally.

          -  ECOG score was 0 or 1.

          -  Have a life expectancy of at least 12 weeks.

          -  The functions of vital organs meet the following requirements (excluding the use of
             any blood components and cytokines during screening) : Neutrophils≥1.5 x 109/L,
             Hb≥9g/dL; Plt≥90 x 109/L, ALB≥3g/dL, TSH≤ULN(Upper Limit Of Norma), TBIL ≤ 1.25 x ULN,
             ALT and AST ≤ 1.5 x ULN, AKP≤ 2.5 x ULN, CR≤ 1.5 x ULN

          -  Female Subjects of childbearing potential must have a negative serum pregnancy test
             within 72 hours before the first dose and must be willing to use very efficient
             barrier methods of contraception for the course of the study through 3 months after
             the last dose of study treatment.

        Exclusion Criteria:

          -  Subjects had any active autoimmune disease or history of autoimmune disease.

          -  Subjects are using immunosuppressive agents, or systemic, or absorptive,local hormone
             therapy to achieve immunosuppression. It is still in use within 2 weeks before
             enrollment.

          -  Subjects with severe allergic reactions to other monoclonal antibodies.

          -  The subjects had a central nervous system metastases of clinical symptoms.

          -  A heart condition or disease that is not well controlled.

          -  Subjects had active infections.

          -  Other clinical trials of drugs were used within 4 weeks prior to the first
             administration.

          -  The subjects have received other PD-1 antibody therapy or other immunotherapy for PD-1
             / PD-L1 or CDK4/6 inhibitor treatment in the past.

          -  There are other factors lead to patients can not participate in this clinical study by
             the judgment of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Yanqiao, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator Harbin Medical University Cancer Hosptital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang Yanqiao, PHD</last_name>
    <phone>138 4512 0210</phone>
    <email>yanqiaozhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Guangyu, PHD</last_name>
    <phone>18249038966</phone>
    <email>18249038966@163.com</email>
  </overall_contact_backup>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yanqiao Zhang</investigator_full_name>
    <investigator_title>Director of the hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

